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Membrane physical biologyWith a projected 382.4 per 100,000 people expected to suffer from some form of malignant neoplasm in
2015, improving treatment is an essential focus of cancer research today. Multi-drug resistance (MDR) is
the leading cause of chemotherapeutic failure in the treatment of cancer, the term denoting a characteristic
of the disease-causing agent to avoid damage by drugs designed to bring about their destruction. MDR is also
characterised by a reversal of the pH gradient across cell membranes leading to an acidiﬁcation of the outer
milieu and an alkalinisation of the cytosol that is maintained by the proton pump vacuolar-type ATPase
(V-ATPase) and the proton transporters: Na+/H+ exchanger (NHE1), Monocarboxylate Transporters (MCTs),
Carbonic anhydrases (CAs) (mainly CA-IX), adenosinetriphosphate synthase, Na+/HCO3− co-transporter and
the Cl−/HCO3
−exchanger. This review aims to give an introduction to MDR. It will begin with an explanation
for what MDR actually is and go on to look at the proposed mechanisms by which a state of drug resistance is
achieved. The role of proton-pumps in creating an acidic extracellular pH and alkaline cytosol, as well as key bio-
mechanical processes within the cell membrane itself, will be used to explain how drug resistance can be
sustained.
© 2013 Elsevier B.V. All rights reserved.1. Multi-drug resistance (MDR)
In order to introduce the subject we will, ﬁrstly, discuss the cur-
rent representation regarding MDR mediated by active membrane
drug pumps and, in a second part, review the many hidden paradoxes
behind the single notion of drug pumping to explain MDR. This
will allow a smooth and natural introduction of other tumouregenic
elements such as the pH gradient across the membrane and the alter-
ation of the physical properties of the membrane.
1.1. MDR mediated by drug pumps
Multi-drug resistance (MDR) is characterised by the development
of resistance to an anticancer drug, which is then accompanied by
resistance to other structurally and pharmacokinetically unrelated
drugs. Ultimately, MDR describes the failure of a diverse range of
drugs to reach and/or act on their targets [1], which include DNA
[2], RNA [3] and tubulin [4]. The phenomenon typically follows
one of two pathways; either as a pre-existing phenomenon discov-
ered after metastatic presentation, or as a metastatic recurrence
following treatment of a primary tumour [5]. The challenge of MDR: +44 115 95 16440.
uch).
l rights reserved.has confounded scientists and clinicians for many years, with a
deﬁnitive solution remaining elusive. Multiple theories have been
postulated regarding the conferment of MDR, implicating the
P-glycoprotein (Pgp) coded by the MDR1 gene (an ATP-binding cas-
sette [ABC] transporter). Studies have revealed that Pgp relies on
the actin cytoskeleton for its localisation in lipid rafts on the cell
membrane thereby facing drugs inﬂux and probably counteracting
uptakes [6,7]. In this context of membrane location mediated by
actin, the interaction between ezrin and Pgp is thought to play a
pivotal role in conferring the tumour cells a metastatic phenotype
[8–10]. The action of Pgp as a drug efﬂux pump to such therapies as
paclitaxel, adriamycin, docetaxel and daunorubicin [11] has led to
the development of chemosensitising agents including verapamil,
cyclosporine and quinine which focus on the inhibition of this pro-
tein, both competitively and noncompetitively [12]. The discovery of
multi-drug resistance associated proteins (MRP), such as ABCG2
(mitoxantrone resistance protein, MXR), has widened the therapeutic
scope for the inhibition of alternative efﬂux pumps which often
share some structural similarity with Pgp, as is exhibited by the
MRP1-encoded ABCC1 [12,13]. However, Pgp expression appears
not to be a prerequisite of the MDR phenotype – another demonstra-
tion of the heterogeneity of tumours – and De Milito and Fais [14]
concluded that ‘…it does not seem that ABC transporters have a key
and direct role in the intrinsic resistance of tumours to anticancer
1 Likewise, one has more chance of winning the national lottery if we buy more than
one ticket.
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pumps in many cases of MDR is irrefutable, it has been shown that
an intracellular alkaline shift alone is sufﬁcient for the failure of accu-
mulation of intracellular chemotherapeutic agents within the appro-
priate compartments of cells [15] accompanied by increased drug
efﬂux and decreased cytosolic accumulation [16]. These data have
resulted in a shift of the concepts used and related therapeutic goal
to combine targeting both Pgp function and pH changes in cancer.
In addition, the introduction of pH in MDR has opened the door to
new “synthetic theories” aiming at understanding MDR as a whole
and not focused only on Pgp-like drug transporters.
A quick review of paradoxes behind the single use of Pgp theory in
MDRwill now highlight the need for new synthetic theories involving
other tumouregenic parameters, especially the pH.
1.2. Paradox one: the drug-pumped-to-ATP-consumed ratio
It was in 1973 that Dano Keld suggested that the mechanism of re-
sistance was due to an outward efﬂux [17]. This hypothesis clearly
gained credance when three years later P-glycoprotein (Pgp) was iden-
tiﬁed by Juliano and Ling as the membrane protein over-expressed in
MDR cancer cells that actively extrude membrane amphipathic drugs
[18]. Since then many biological, biochemical and structural studies
have been carried out on this family of ABC transporters. To summarize,
a conformational change in the structure of Pgp upon ATP binding
allows access from the lipid bilayer inner leaﬂet to the internal cavity
of volume ~6000 A3 [19–23]. Drug binding to Pgp is more sensitive
to ATP binding rather than hydrolysis, and two ATP molecules need
to be bound on Pgp to allow its full activation [23–28]. The use of
crystallography methods and basic biology found that the turnover
rate of Pgp ATPase is in the range of ~1–15ATP/s [29–31] with a
near stoichiometric substrate transport to ATP hydrolysis ~2ATP/
drug, reviewed in [32].
At the molecular level everything sounds ﬁne but what remains
unclear however is the low efﬁcacy of Pgp in reconstituted systems.
The apparent stoichiometry of the hypothesised ATP coupled active
drug transport, i.e. the number of ATP molecules hydrolysed per
drug transported, can be enormous (calculated to be up to ~36,000
ATP/drug in reconstituted proteo-liposomes) [33–35]. This suggests
thatwhilst consuming ATP, Pgp does not necessarily lead to drug extru-
sion. It seems therefore that Pgp-like transporters oscillate between
open and close conformations without involving and transporting
drugs. Although the history of biology (and evolution in particular)
taught us that biological systems do not need to be fully efﬁcient to
keep their robustness, it is notable nonetheless that if Pgp was inefﬁ-
cient MDR would not be a problem in clinical oncology. Two paths are
now available, either Pgp and relatives are not involved in MDR at all
(that is unlikely to be the case) or something else must help Pgp and
relatives to gain enough efﬁcacy for MDR to be noticable by clinicians.
1.3. Paradox three: the role of drug molecular weight (MW) in drug
resistance
Today, it is suggested that the ability of many drugs to bind the
internal cavity of Pgp is linked to the number of potential binding
sites available on the wall of the internal cavity composed of hydro-
phobic, aromatic, polar and charged amino acid residues [19].
Altought the later statement is sound from a biochemical point of
view, it is important to note that the MW of drugs (namely their
size or volume) is known to be a strong predictor of MDR levels in
Pgp expressing cells [36–38]. This point was ﬁrst demonstrated in
1970 [36]. The date is important here as this seminal study on drug
resistance comes three years before Dano Keld's “vacuum cleaner”
hypothesis (Dano, 1973) and six years before the discovery of Pgp
[18]. So albeit the notion of drug pumping was inexistent at the
time (1970), the drug MW was the main parameter describing MDRthen. Why this type work based on drugs MW was not carried for-
ward is not clear but what is remarkable however, is that decades
later the pharmaceutical industry discovered that the MW of drugs
is indeed paramount for their systemic delivery (bioavailability) and
largely responsible for attrition [39]. From the pharmaceutical point
of view, the bioavailability of a drug depends also on its ability to
cross the multiple membrane layers present in a body (i.e. cells)
and, accordingly, it was demonstrated that lipid bilayer membranes
do indeed play a fundamental role in drug bioavailability based on
their MW [37,40]. The fundamental reason behind this is related to
the biomechanical interaction between the drug volume and the sur-
face tension of the cell membrane namely the physical packing of
lipids in either leaﬂet of the cellular membrane (controlled by cells
themselves).
So maybe without noticing it, Bielder and Rhiem discovered in
1970 [36] a fundamental Law in basic drug delivery [37,40].
1.4. Paradox three: the lack of speciﬁcity
As stated by the term used namely “multi drug resistance”, a single
transporter should be able to transportmany different drugs not related
structurally and chemically. Although the molecular model of Pgp has
permitted a relatively simple representation of MDR in agreement
with the usual concepts issued from the ﬁeld of biochemistry, how a
single protein can expel structurally different drugs is still poorly un-
derstood. Indeed, “controversy remains over how P-gp recognizes hun-
dreds of different hydrophobic drugs and pump them out of the cell…”
[41]. Beyond this last remark, there is something far more signiﬁcant
and important at stake: the Pgp-mediated MDR model does not con-
form to the fundamental notion of speciﬁcity and seems to challenge
the roots of biochemistry. This conceptual issue was exposed early
and very clearly by Paul Roepe: “…MDR cells are resistant to, and/or ex-
hibit decreased retention of, literally hundreds of different hydrophobic
compounds that are structurally divergent… Membrane transporters,
like soluble enzymes, are exquisitely substrate-speciﬁc…If transporters
were not speciﬁc, the cell would eventually become a high entropy cha-
otic mess…[as there are] no structural molecular motifs common to all
the many different agents to which MDR cells are resistant…MDR pro-
tein is a very unusual enzymewith extraordinarily broad substrate rec-
ognition capabilities; that is, it violates the law of enzyme speciﬁcity”
[35]. Given the paramount importance of the notions of “speciﬁcity”
or “afﬁnity” in classical biochemistry therewas anobvious need to rede-
ﬁne Pgp efﬁciency.
It is common to deﬁne the binding-afﬁnity as the likelihood of
drug and transporter interacting uponmeeting and in this case the in-
teraction energy becomes a fundamental variable. However there
exist chemical reactions that are relatively inefﬁcient and one way
to increase the rate of products formed is to raise the temperature.
By doing so it is not the interaction energy that is affected but the
rate of collisions between chemicals that is increased. By increasing
collision rates the chance of a product being formed increase as
well.1 Random processes have been studied for more than a century,
and it is now well established that the mathematical properties of
Brownian diffusions are fully dependent on the dimensions of space.
In particular, there is one theorem, known as Polya's Theorem, that
states that portions of space are always left unvisited (whatever the
visitation time considered) if the Brownian particle diffuses in dimen-
sions higher than 2 and that, conversely, in dimensions smaller than
or equal to 2, all the space will be visited possibly more than one
time over a long enough period of time, reviewed in [42]. Recalling
that the MW of drugs is important and involved in their residency
time in membrane (of course function of the membrane physical
properties), the larger the drug the better to improve Pgp-mediated
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between open and close conformations (paradox one). In this condi-
tion, the diffusion of drugs in the membrane warrants the ability of
drugs and transporters to interact without the use of interaction ener-
gy (i.e. drug-Pgp afﬁnity).
Altogether the points above highlight the fact that albeit Pgp and
relatives are responsible for drug resistance levels they cannot do it
alone and that, the membrane is very likely involved in this process.
The next point to clarify is to ﬁnd the parameters allowing the phys-
ical changes necessary to impact on the membrane to sustain Pgp
function (i.e. drug pumping). For this it is central to review the role
of proton dynamic and pH in cancer.
2. The role of pH in cancer progression and the related
Warburg's hypothesis
Central to MDR research is being able to understand the physiolo-
gy of cells and how this differs in cancer. A key event, cause or conse-
quence, in the transformation of normal cells into cancerous cells was
discovered by Otto Warburg in 1924. His observations described the
switching of cellular respiration to glycolysis, even under aerobic con-
ditions, and this was further discovered to be at least partly as a result
of the loss of mitochondrial inhibition of glycolysis [43].
Despite the relative inefﬁciency of glycolysis (Fig. 1) and the in-
creased metabolic demand for adenosinetriphosphate (ATP), cancer-
ous tumours still undergo this switch to glycolysis.
In 1956, Otto Warburg identiﬁed a shift in pH surrounding cancer
cells that was found later to be related to an up-regulation of proton ex-
changemechanisms across themembrane, themselves related to glycol-
ysis. It is now well established that, in cancer cells, the alkalinisation of
intracellular pH (pHi) is accompanied by acidiﬁcation of the extracellu-
lar environment (pHe) [44]. This phenomenon is considered to directly
drive the post-transformation neoplastic phenotype and is directly in-
volved in the activation and etiopathogenesis of the metastatic process
[45–48].
A low pHe, together with hypoxia, results in loss of apoptotic
control through activation of intracellular pathways; for example, theFig. 1. The relative inefﬁciency of glycolysis (a 2 ATP yield, compared to 36–38 ATP with ox
cells, which requires large amounts of energy for proliferation. Loss of mitochondrial inhibiti
of lactic acid, which dissociates into lactate and H+.extracellular-signal-related kinase (ERK1/2). This pathway is critical to
proliferation, transformation, tumourigenicity, invasion, angiogenesis,
differentiation and survival [49], and is controlled by the oncoproteins
Ras and Raf (Fig. 2). Upon activation through phosphorylation, ERK1/2
translocates to the cell nucleus in order to phosphorylate its gene tar-
gets. Acidic conditions have been shown to upregulate the phosphoryla-
tion of ERK 1/2 [50], and the expression of ERK1/2 in mucoepidermoid
carcinoma correlateswith both the aggression of tumours and the over-
all clinical outcome [51]. It is also worth mentioning that additional
studies have demonstrated a role for Bcl-2 and GPR65 as mechanisms
of resistance to apoptosis mediated by pH [52].
A major consequence of up-regulated glycolysis is the increased
production of metabolic acids responsible for the presence of acidic
areas within solid tumours. Autophagy is a cellular catabolic pathway
leading to lysosomal degradation and recycling of proteins and organ-
elles. Studies have demonstrated that induction of autophagy may
represent another adaptation mechanism for cancer cells exposed to
an acidic environment [53,54].
In addition to activation of ERK 1/2, the hypoxic and acidic
tumoural environment also leads to the increased release and activa-
tion of acidic proteases such as cathepsin B [55,56], MMP2 [57] and
MMP9 [58], which are overly expressed in tumour ECM, contributing
to the degradation of the extracellular matrix, thus promoting inva-
sion and metastasis [59]. Furthermore, acid- and hypoxia-induced
up-regulation of ERK 1/2 increases vascular endothelial growth factor
(VEGF) expression through hypoxia-inducible factor 1 (HIF-1), there-
by promoting angiogenesis [60–63], which is then permissive to fur-
ther growth and metastasis.
Further studies have concurred that one of the deﬁning character-
istics of the tumour microenvironment is the reversal of the pH gradi-
ent across cell membranes [46,59]. This aberrant intratumoural pH
gradient can also be accredited, in part, to two main events: (i) the
intracellular proton overproduction following the dissociation of
lactic acid into lactate and hydrogen ions, as end-products of the
up-regulated glycolytic pathway and; (ii) the over-expression or
over-activity of proton exchange or acid extrusion mechanisms
[44,64,65]. This gradient is exaggerated in metastases and increasesidative phosphorylation) makes this a counter-intuitive metabolic pathway for cancer
on of glycolysis mediates this switch, and results in the accumulation of large quantities
Fig. 2. Overview of a cell-signalling pathway, using ERK1/2 as an example. Hypoxia and low pH stimulate Ras protein here. Many cancers stem from a mutation in one protein in a
pathway, which leads to uncontrolled activation and signal deregulation, thus activating the whole pathway and leading to transformation and tumourigenesis. Other regulatory
pathways often implicated in neoplasia include PI3K/Akt/mTOR.
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of all malignant tumours is emerging as one of the most signiﬁcant and
selective hallmarks of cancer [48]. See Fig. 3 for a schematic overview of
these relationships.
3. The role of proton pumps and transporters in maintaining a
reversed pH gradient in tumours
Accumulation of intracellular acidity is clearly intolerable to can-
cer cells and must be counteracted by the use of a detoxiﬁcation
mechanism [67] as there is clear evidence that inhibiting proton
pumps leads to an early intracellular acidiﬁcation and accumulation
of toxic chemicals (e.g. ROS) followed by caspase activation in differ-
ent tumour histologies [68,69]. This is achieved by proton pumps and
transporters which are found both in the lipid bilayer of the external
cell membrane and in intracellular compartmental membranes. These
pumps/transporters, through various mechanisms, have the net effect
of externalising protons, ultimately leading to a drop in the pH of the
extracellular ﬂuid (ECF) within the tumour (Fig. 3). It is however im-
portant to underline that the type of acid extrusion is different be-
tween the direct transport of proton from the cytosol across the
plasmalemma and the accumulation of proton from the cytosol inside
lysosomes to saturating levels followed by the exocytosis of their con-
tents via the endosomal/lysosomal trafﬁcking system. This review fo-
cuses on the proton pump V-ATPase and the proton transporters
NHE1 and MCTs and the HCO3− transporters.
3.1. V-ATPase
Vacuolar type H+-ATPases (V-ATPases) have been identiﬁed as
mediators of the acidic microenvironment of tumours [70] and asplaying a key role in the MDR phenotype [71]. The up-regulation of
the pump and its associated increased intracellular alkalinisation
has also been implicated in cell transformation and cisplatin resis-
tance [72]. V-ATPases are expressed in the plasma membrane [73]
and membranes of intracellular vacuoles [67,74], such as lysosomes
and endosomes, resulting in their acidiﬁcation [75]. The sequestration
and inactivation of chemotherapeutic agents in these acidic, endocy-
totic compartments and their subsequent extrusion from the cell is
believed to contribute to resistance, in addition to the drug efﬂux
mechanisms mentioned above. Peréz-Sayáns concluded that induced
expression of V-ATPases in MDR is an anti-apoptotic defense: the
up-regulation of V-ATPases in most human tumour cells [67,72,76]
together with their fundamental role in cellular detoxiﬁcation [67],
suggests that these pumps might present a viable therapeutic target
in the overcoming of MDR.
3.2. NHE1
The membrane-bound NHE1 transporter is a sodium/hydrogen ex-
changer present at the surface of most cells where it has a central role
in cellular volume and pH homeostasis [75,77–80]. Hypoxic tumour
conditions have been shown to mediate the activity and expression of
NHE1 through up-regulation of the transcriptional regulator, hypoxia-
inducible factor 1, (HIF-1) [81] and the exchanger has been cited as
the primary mediator of acidic tumoural ECF [57,59,75]. Recent studies
have also deﬁned an additional role for NHE1, localised at the leading
edge of pseudopodia and lamellipodia of cancer cells involved in tissue
invasion [59,75]. This process is mediated through activation of
phosphoinositide-3-kinase (PI3K) [82] and p38 mitogen-activated
protein kinase (p38MAPK) [83] pathways. It is postulated that the ex-
trusion of protons by NHE1 results in proteolysis and degradation of
Fig. 3. Proton pumps and transporters are responsible for the cellular detoxiﬁcation mechanisms, as referred to the H+-efﬂux of cancer cells, resulting in a reversal of the normal pH
gradient. Drugs are sequestered and inactivated in intracellular acidic compartments, which in turn dissipate their contents into the tumoural environment, also contributing to the
hyperacidiﬁed extracellular microenvironment of malignancy.
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lytic enzymes, thus facilitating subsequent invasion, [83–85] and me-
tastasis [86]. Indeed, recent work has demonstrated that NHE1 is
localised at the invasive structure of aggressive cancer cells, called
invadopodia, and is necessary for both their formation and proteolytic
activity; [87,88] and that its activity can be stimulated by hypoxia
[89]. In support of this idea of the importance of NHE1 in invasion is
the recent paper looking at the distribution of proton transporter pro-
tein in tissue sections of rat brain C6 gliomas where the NHE1 was
most heavily expressed at the invasive edge of the tumour [90].
Direct inhibition of NHE1 or V-ATPases, which are believed tomedi-
ate the malignant ΔpH, has been identiﬁed as giving rise to cytostasis
and/or cytotoxicity. For example, whilst inhibition of NHE1 has been
shown to have cytostatic effects in malignant glioma [91], hepatocellu-
lar carcinoma cells [57] and breast cancer cells [92].; V-ATPases inhibi-
tion gives rise to cytostasis and cytotoxicity in oral squamous cell
carcinoma [93], B cell lymphomas [94], doxorubicin-resistant renal cell
carcinoma [95], breast carcinoma [96], hepatoblastoma [76], melanoma
[68] and pancreatic cancer [97,98] cells. Whilst cytostasis is obviously
encouraging in cancer therapy, reﬂecting a lack of disease progression,
cytotoxicity is regarded as more desirable as it characterises regression.
Based on theseﬁndings, NHE1 andV-ATPase represent potentially valu-
able and speciﬁc targets for the mediation of disease progression and
metastasis. Further studies, in which resistant cells and tumours have
been treated with inhibitors of these pumps, prior to or together with
a chemotherapeutic agent, have yielded encouraging results in the re-
versal of tumour resistance [14,99–102] and NHE1 inhibition has been
found to augment paclitaxel [103], imatinib [104], doxorubicin [105]
and cisplatin sensitivity in breast cancer cells [106].
3.3. MCTs
There are a total of 14 MCTs; encoded by the solute carrier family
(SLC) 16 [107]. MCT1–4 are proton symporters involved in thetransmembrane transport of lactate, pyruvate and ketone bodies.
The up-regulation of factors mediating hypoxic stress such as
HIF-1α is a well documented phenomenon in the cancerous tumour
environment [108–113]. It has been demonstrated that HIF-1α in-
creases the expression of MCT4 [114], an important pH regulator.
MCT4 not only brings about the expulsion of hydrogen ions, in an at-
tempt to decrease pHe, but is also involved in the removal of lactate
from the intracellular cytosol, allowing continuous conversion of glu-
cose to lactate. The role of MCT1 in cancer cell invasiveness could be
explained by the extracellular expulsion of lactate and hydrogen
ions [115], leading to vascular incursion. The importance of MCTs in
cancer cell survival has been indicated in studies showing that inhibi-
tion of MCT1, both in vitro [116–118] and in vivo [118], resulted in a
decrease in pHi and retarded tumour growth respectively. Whilst
much less is known about the role of MCT in tumour cells, compared
to NHE1 and V-ATPases, recent research suggests that it has a major
role in cell survival in the hyper-glycolytic and acidic conditions
brought on by a hypoxic tumoural environment.
3.4. HCO3
− transporters
HCO3− transporters facilitate the transversemovement of HCO3− ions
that is too hydrosoluble to cross lipids membrane otherwise. Doing so,
the drop in pHi associated with the metabolism of cancer cells can be
buffered into the release of CO2 and H2O but also changes in the mem-
brane potential of the cells. Two classes of HCO3− transporters are funda-
mental to drive this reaction namely the Cl−/HCO3− exchangers (AEs)
and the NBCs family of Na+/HCO3− co-transporters. The function of
some AEs involves also the carbonic anhydrase isoforms (CAs) to
which they form complex with known as metabolon [119], this has
been demonstrated for the AE1-CA2 metabolon [120]. Altogether they
allow a net increase in pHi. The NBC family of co-transporters is com-
posed of electrogenic (i.e. 3:1 or 2:1 HCO3−:Na+ stochiometry) and
electroneutral transporters. Their interaction with membrane of the
2 The “vacuum cleaner”model was ﬁrst put forward in 1972 to explain why drugs do
not diffuse into cells that are resistant to drugs. It was then suggest that cells “vacuum
clean” drugs. It is remarkable that such elusive hypothesis stood up time until recently.
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[121]. A role for anion exchangers and related pH metabolism in
multidrug resistance was ﬁrst demonstrated by Paul Roepe in 1997
[122].
4. MDR and pH
As stated above, disease progression and metastases are associat-
ed with an exaggerated pH gradient reversal, notably an elevated in-
ternal pH (pHi). This gradient reversal has, in turn, been shown to
correlate with the development of MDR [15,46,72,123]. This leads to
the conclusion that the reversed pHebpHi gradient somehow inter-
feres with the passage of drugs across the lipid bilayer of cells. Such
a supposition seems plausible for the many anti-cancer drugs
that are weak bases (such as doxorubicin and mitoxantrone), which
are neutralised and inactivated by protonation in the acidic microen-
vironment surrounding the cells which they are intended to pene-
trate, or sequestered in intracellular acidic vesicles or endosomes
[15,102]. However weak acids and water-soluble molecules (such as
methotrexate and 5-FU, respectively) for which the malignant acid–
base status ought not to be so problematic, still encounter consider-
able barriers in poorly-vascularised, solid tumours in the form of
polyglutamation and malperfusion [124]. A fundamental question
remains: how the pH alteration could also be involved in triggering
the MDR state bypassing all the electrochemical properties of drugs
and membrane?
All anti-cancer drugs aimed at intracellularly targets will have to
cross the cell membrane. Therefore, understanding the biochemical
and biomechanical interactions of drugs with the membrane includ-
ing how they penetrate, accumulate or are extruded represents an
important focus in developing future chemotherapy treatments.
Up-to-now, we have discussed the role of proton pumps in MDR.
For the next part of the review, the biomechanical properties of the
cell membrane itself will be examined; it will then become clear
that the membrane itself is involved in the MDR state.
5. Fluid mosaic model and MDR
Current MDR theories concerning interactions between drugs and
the membrane utilise the ‘ﬂuid mosaic model’ [125] to explain the
interaction between drug and cell. It is widely accepted that the phys-
ical and chemical properties of the phospholipid bilayer with a hydro-
philic outer and hydrophobic inner make a selectively permeable
barrier facilitating passive and energy-utilising transport across it
[125]. The apical and basolateral membranes contain intrinsic and ex-
trinsic structures which, together with the membrane, are thought to
be managed via endocytosis and exocytosis in a process called “mem-
brane trafﬁcking”, in which membrane components are regularly
renewed and replaced [126]. A number of membrane properties are
of interest in MDR including the ﬂuidity and associated lipid density
of the membrane. Whilst lipids cooperate with one another via
non-covalent interaction of their hydrophobic tails and hydrophilic
heads, the overall ﬂuidity of the membrane can be adjusted by the
level of saturation of the phospholipid molecules [126]. Where a
high density of saturated molecules occurs together with cholesterol
and often sphingolipids, distinct micro-domains or “lipid rafts” of
highly stiffened regions on the membrane may form [127]. Another
important element of the ﬂuid mosaic model in MDR is the concept
of lateral mobility of membrane components via interactions be-
tween the polar and non-polar regions of the proteins and lipids.
This lateral heterogenecity in lipid bilayers has been termed “liquid-
ordered micro-domains” and indicates regions with differing chemi-
cal and physical properties to other areas of the membrane such as
decreased ﬂuidity in lipid raft regions [126]. MDR research utilises
the complexity of these systems and the associated intrinsic andextrinsic proteins to interpret the process of drug interaction with
the cell.
6. Biomechanics in MDR
The relevance of biomechanics inMDR research relates to the ability of
the drug to negotiate the membrane and includes the ﬂuidity, relative
lipid density and surface tension of each of the leaﬂets within the mem-
brane [128,129]. For example, it has been suggested that ‘an excess of
packing of lipid in the inner membrane of MDR cells is responsible for
blocking drugs mechanically as a function of their sizes at the membrane
level’ [37,40,130].Management of themembrane is facilitated via the pro-
cesses of endocytosis and exocytosis and it has been shown that rates of
endocytosis in MDR cells are higher than in sensitive parent cells [131].
A fundamental concept ofmembranebiomechanics is the relationship be-
tween endocytosis and the differential packing of lipids between mem-
brane leaﬂets. Conditions of increased endocytosis have been associated
with higher levels of endogenous compression of the inner leaﬂet of the
membrane where mechanical packing of lipids in the inner leaﬂet has
been found to drive endocytosis [132].When vesicles are formed the sur-
face area of the outer leaﬂet is larger than that of the inner leaﬂet and
therefore the outer leaﬂet must contain a larger number of lipids than
the inner leaﬂet (Fig. 4A). During the budding stages of endocytosis, the
outer leaﬂet of the vesicle is formed by the inner leaﬂet of themembrane
and, therefore, the inner leaﬂet of the membrane must contain a propor-
tionately higher density of lipids [130,37] (Fig. 4B).
In this respect, MDR cells have been found to have a two- to
ten-fold increase in their kinetic rate of endocytosis which would sug-
gest that they have a much higher lipid density within the inner leaf-
let of their membrane compared to drug-sensitive cells [40]. There
are two types of endocytosis distinguishable in cells including ‘recep-
tor mediated endocytosis’ (RME) and ‘ﬂuid phase endocytosis’ (FPE).
RME utilises a form of membrane coating such as clathrin that creates
pits or bends in the membrane resulting in vesicles surrounded by a
membrane coating [133]. Cytokines and growth factors utilise RME
to mediate signalling pathways [134]. FPE is a more passive process
with no receptor mediated interactions prior to vesicle formation
[135]. FPE vesicles are continuously formed and have been linked
with membrane recycling [132]. FPE requires there to be a degree of
asymmetry in the phospholipid number between the inner and outer
leaﬂets of the membrane as this asymmetry provides the mechanical
moment required to generate membrane curvature and budding
[136]. This asymmetry is thought to be mediated by transmembrane
proteins called ‘ﬂippases’ [137] which have been also highlighted as
being important in potential Pgp mechanisms of action. Rauch and col-
leagues have hypothesised that the altered endocytosis kinetics seen in
drug resistant cells with resultant increases in the difference in surface
tensions betweenmembrane leaﬂets will affect themechanical interac-
tion between the drug and the membrane. This concept suggests there
is a critical cross-sectional area of drug size beyond which the differ-
ences in surface tension on the membrane will affect the transit time
of the drug through the membrane. Similarly, drugs with different
physical properties such as high molecular weight (as it relates to the
drug size) will be affected by cellular MDR changes in different ways.
Conversely, a lowmolecular weight will be less affected by lowermem-
brane ﬂuidity and be able to cross the membrane more easily.
There is a double advantage in increasing the mechanical packing
of lipids within the inner membrane: not only will this increase the
‘trapping’ of drugs within the inner leaﬂet of the membrane (as de-
scribed in Fig. 4C) and therefore increase the residency time of the
drug within the membrane but also, it will allow a full explanation
of the ‘vacuum cleaner’2 model mediated by drug transporters to
Fig. 4. (A) Lipid asymmetry within vesicle membranes (Adapted from [37]). For small vesicular sizes, the relative surface areas between the outer and inner leaﬂet are not negligible
that, in turn, indicates that vesiculation is only possible if more lipid are added one leaﬂet compared to the other. (B) Hypothetical Model Linking Fluid Phase Endocytosis and
Exocytosis to Membrane Lipid Asymmetry (Adapted from [150]). In that case, the lipid number asymmetry is induced by a membrane ﬂippase (the aminophospholipid translocase).
(C) Membrane Energy Barriers. The inner leaﬂet contains a higher density of phospholipids and therefore an increased surface tension. The energy proﬁle of the lipid packing is
represented by the solid line on the graph. The energy proﬁle of the hydrophobic core of the membrane is represented by the dashed line. As drugs cross the membrane they
will become trapped in the inner leaﬂet, impairing their ﬂow into the cytoplasm of the cell. Drugs with a higher molecular weight will feel this effect more strongly increasing
their probability of meeting a drug transporter. (Adapted from [40]).
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the drug within the inner leaﬂet increases the probability that via lat-
eral diffusion the drug will contact one of the multi-drug transporters
and be removed from the membrane (Fig. 5). As a result, membraneFig. 5. 2D ‘Random Walk Model’ of drug and drug transporter interaction.
Adapted from [130].changes in the speciﬁc way described are not only necessary but
entangled with the notion of multidrug resistance.
Therefore, inclusion of the biophysical properties of the membrane
into MDR theory does have the potential to build on the more classical
theories of MDR and make them closer to actual observations.
7. Membrane biomechanics and ‘Pgp’
Biomechanics provides an additional argument as to why cells can
become resistant to multiple drugs rather than just the drug to which
they are being exposed and in this way can help explain the link of
MDR to the non-speciﬁcity of Pgp transporters. Fig. 4C shows that
all drugs will experience some degree of impairment by the mem-
brane, which is non-speciﬁc and thus represents a potential mecha-
nism of action that acts in a totally non-speciﬁc manner. In the case
where drugs have a very small molecular weight and are not seriously
impeded by the membrane, the probability of lateral diffusion of the
drug to meet a transport protein decreases due to the decreased res-
idence time of the drug within the inner leaﬂet [40]. Where this
scenario occurs, Rauch [40] suggests that levels of cross-resistance
would then become solely a function of the mechanical packing of
the lipid and the molecular weight of the drug, lessening any affect
of multidrug transporters such as Pgp.
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far been discussed independently of one another. The next step is to
merge MDR, pH changes as observed and measured in cancer and
the physical biology of the cellmembrane. Thiswill help to better under-
stand both how the altered pHe to pHi gradient in tumours alters the
membrane dynamics andhow the action of proton transporter/pump in-
hibitors can result in a blocking of MDR through the re-establishment of
‘normal’membrane lipid dynamics.8. Lipid density theory and pH interaction
It has been hypothesised that the resistance attributed to proton-
pump associated ΔpH reversal may also be mediated through
the biophysical properties and packaging of membrane phospho-
lipids [37]. The individual phospholipids of a lipid bi-layer such as
phosphatidylserine, which is found predominantly in the inner mem-
brane leaﬂet [138–140], carry a negative charge in their polar region
(see Fig. 6). As positive charges will therefore be electrochemically
attracted to the region, any free protonswill accumulate in close vicinity
to the membrane. In drug-sensitive cells, this effective neutralising of
themembrane nanoenvironmentwill lead to decreased electrostatic re-
pulsion between the polar groups of the phospholipids, thus optimising
the membrane ﬂuidity for successful drug penetration. It therefore
follows that in a resistant cell, the up-regulation of proton pumps
will lead to depletion of the intracellular supply of protons, such that
the inner membrane will continue to carry a negative charge, thusFig. 6. Illustration of the lipid-packing theory. (A) Drug-sensitive cell, showing theoretical ‘n
ical attraction of protons to negatively-charged phospholipids such as phosphatidylserine.
and potentiating drug permeability. (B) Drug-resistant cell, in which the externalisation of
lipids. This effectuates a ‘stiffening’ of the membrane, which renders the passage of drugs m
within the membrane, see Rauch (2009).permitting increased repulsion and tighter packing of membrane
phospholipids – effectively ‘stiffening’ the membrane – which, in turn,
decreases permeability to chemotherapeutic drugs [37]. As a result, a
pH difference of about 0.2 units is enough to block classical chemothera-
py drugs with a molecular weight around 500 (Fig. 7A) [37,40]. More-
over, the rate of ﬂuid-phase endocytosis will increase as a result of
increased membrane lipid packing forcing infolding of the membrane.
Thiswill lead to the endocytosis of the previously blocked and/or efﬂuxed
drugs, which are sequestered into the aforementioned intracellular vesi-
cles [37,141]. This postulated mechanism is supported by the decreased
cytotoxic effects of doxorubicin ([142,143], mitoxantrone [144] and vin-
blastine [145] in the acidic microenvironment of tumours [146].9. pH and APOPTOSIS with or without drugs
Whereas the precise role of pH in apoptosis has yet to be clariﬁed, it
has been discovered that intracellular acidiﬁcation is key to the cellular
process of programmed cell death.Whether intracellular acidiﬁcation is
the trigger or simply an ampliﬁer of apoptosis is still unknown. Howev-
er, pH changes are paramount to drug resistance.
It therefore follows that an alkaline intracellular pH can promote
cancer cell survival. As discussed above, alkaline pHi can be brought
about via the activation of ion carrier (or exchanger) in the cell mem-
brane, for example the Na+/H+ exchanger (NHE1). In cancer cells
upregulation of this transporter has been recognised as a mechanism
for extruding hydrogen ions and, therefore, creating an alkaline pHi.eutralisation’ of the intracellular membrane microenvironment, through electrochem-
This results in decreased electrostatic repulsive forces, maintaining membrane ﬂuidity
protons results in increased electrostatic repulsion between polar regions of phospho-
ore problematic. For a more detailed schematic of the biophysical forces acting on and
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Fig. 7. (A) Relationship between cytosolic pH changes and drug resistance levels for different cell types. In all these cells the drug sensitive phenotype has a cytosolic pH of about 6.9.
Blank dots represent the experimental measurements (the black line corresponds to the experimental trend); the black dots represent the predictions from the theory (from [40]).
(B) Basic schematic illustrating the some of the complex inter-relationships of mechanisms of malignant transformation and tumourigenesis described thus far, which play a critical
role in the development of resistance. Note in particular the complete cycle of hypoxia and malignant progression (red arrows) is described fully by Höckel [151]. Elsewhere, it is
evident that inhibition of only one factor may prove unsuccessful due to the number of alternative routes available for disease progression.
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anti-cancer therapies [46,147]. Downregulation of this transporter,
or alteration of its activity, results in the accumulation of hydrogen
ions within the cells (from the dissociation of lactate), which leads
to intracellular acidiﬁcation and contribute to cell death via apoptosis
[46,147,148].
The Warburg effect, as previously discussed, describes a switch in
metabolism from oxidative phosphorylation to glycolysis in cancer-
ous cells. Reversal of this characteristic change in cancer cells could
understandably be believed to cause apoptosis in these cells. Several
mechanisms for the reversal of Warburg's effect have been proposed;
for example, the use of 2-Deoxyglucose which inhibits the action of
hexokinase, a rate-limiting enzyme in glycolysis [149]. Inhibition of
glycolysis reduces the amount of ATP energy within the cell and,
therefore, stimulates AMP-activated protein kinase, which in turn
promotes cell death via apoptosis. Inhibition of glycolysis can also
be brought about by reducing the pHi as this downregulates theactivity of hexokinase, pyruvate kinase and phosphofructokinase —
all key enzymes which promote glycolysis [149]. A reduction in gly-
colysis has been suggested to affect the pentose pathway and, there-
fore, affect nucleic acid production in cancerous cells leading to
apoptosis.
Finally, as seen the pH is also expected to bemore than a reasonable
target for any chemotherapeutic treatment whatever the physical-
chemical properties of the drugs.
10. Conclusion: when science and societal needs converge
This review nails the current potential interrelated mechanisms of
physiological pH alteration and MDR in cancerous cells (Fig. 7B sum-
marizes some of inter-relationships involved in transformation, and
tumourigenesis that plays a critical role in MDR). MDR has been de-
ﬁned, and the indirect role of the proton pumps/transporters NHE1,
V-ATPase and MCTs have been examined. In addition, the
615C. Daniel et al. / Biochimica et Biophysica Acta 1832 (2013) 606–617biomechanical properties of the cell membrane have been evaluated
to provide the theory behind the development of a drug-resistant
state.
All together, the works carried out in the ﬁeld of cancer and MDR
over the last 20 years point towards the pH regulatory mechanisms
as a unique target to affect tumour development or survival. Provided
the lack of effective cancer treatments, or engineered drugs (namely
“magic bullet” awaited for too long now and often too expensive),
wouldn't it be more productive as far as human lives are concerned
to concentrate on simple, generic and cheap compounds that are
used on a daily basis to regulate pH? Let us think about well known
and highly efﬁcient molecules blocking stomach acid reﬂux (e.g.
omeprazole) or even the simple use of bicarbonate of soda for exam-
ple? Why are these compounds not used in large clinical trials right
now? Is it because the idea of targeting pH looks too simple and
that as a result fundings are scarce from public research councils; or
is it because these molecules are not patentable anymore?
As scientists we aim to do outstanding far-reaching science with
no ounce of a doubt; but as a simple human being able of some empa-
thy towards others it is important to realise that people are dying
from cancer and that families are destroyed by the disease. There is
a real need to open extra scientiﬁc debates to clarify and let patients
know our scientiﬁc strategy against cancer. As a result, it is important
to redeﬁne strategy with patients, and that can be developed easily.
Targeting the pH of cancer cells may well be one of these solutions.
In this context the authors would like to acknowledge and present
the International Society for Proton Dynamic in Cancer (ISPDC) creat-
ed few years ago (2009) that is a societe savante regrouping all scien-
tists in the world involved in research on proton exchangers, acidity
and cancer, in order to create an efﬁcient and meaningful network
aimed at leading new therapeutic strategies in the ﬁeld of clinical
oncology.
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